Nachman Norwood & Parrott Inc raised its holdings in shares of Baxter International Inc (NYSE:BAX) by 4.8% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,269 shares of the medical instruments supplier’s stock after acquiring an additional 150 shares during the quarter. Nachman Norwood & Parrott Inc’s holdings in Baxter International were worth $266,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in the company. Moody National Bank Trust Division boosted its position in shares of Baxter International by 180.0% in the 1st quarter. Moody National Bank Trust Division now owns 980 shares of the medical instruments supplier’s stock valued at $80,000 after purchasing an additional 630 shares during the period. Ferguson Wellman Capital Management Inc. boosted its position in shares of Baxter International by 18.2% in the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 19,641 shares of the medical instruments supplier’s stock valued at $1,597,000 after purchasing an additional 3,023 shares during the period. Pacer Advisors Inc. acquired a new stake in shares of Baxter International in the 1st quarter valued at about $3,486,000. Curbstone Financial Management Corp acquired a new stake in shares of Baxter International in the 1st quarter valued at about $409,000. Finally, Manning & Napier Group LLC acquired a new stake in shares of Baxter International in the 1st quarter valued at about $243,000. 86.41% of the stock is owned by institutional investors and hedge funds.

In other Baxter International news, Director Thomas T. Stallkamp sold 3,187 shares of the stock in a transaction on Friday, January 18th. The stock was sold at an average price of $70.00, for a total transaction of $223,090.00. Following the sale, the director now owns 9,418 shares in the company, valued at approximately $659,260. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Thomas T. Stallkamp sold 1,638 shares of the stock in a transaction on Friday, February 1st. The shares were sold at an average price of $73.75, for a total value of $120,802.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 98,286 shares of company stock valued at $7,399,039. Company insiders own 0.70% of the company’s stock.

BAX traded down $0.33 on Thursday, hitting $79.83. 1,902,840 shares of the company traded hands, compared to its average volume of 3,090,723. The company has a market cap of $40.97 billion, a PE ratio of 26.17, a P/E/G ratio of 1.94 and a beta of 1.02. Baxter International Inc has a 12-month low of $61.05 and a 12-month high of $82.25. The company has a quick ratio of 1.50, a current ratio of 2.09 and a debt-to-equity ratio of 0.44.

Baxter International (NYSE:BAX) last issued its earnings results on Thursday, January 31st. The medical instruments supplier reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The business had revenue of $2.84 billion during the quarter, compared to the consensus estimate of $2.80 billion. Baxter International had a return on equity of 19.10% and a net margin of 14.60%. As a group, sell-side analysts expect that Baxter International Inc will post 3.27 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Monday, April 1st. Stockholders of record on Friday, March 1st were paid a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date was Thursday, February 28th. Baxter International’s dividend payout ratio (DPR) is 24.92%.

BAX has been the subject of a number of research analyst reports. Morgan Stanley raised Baxter International from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $66.00 to $77.00 in a research report on Wednesday, January 2nd. Citigroup raised Baxter International from a “neutral” rating to a “buy” rating and upped their target price for the company from $69.00 to $76.00 in a research report on Wednesday, January 2nd. Zacks Investment Research raised Baxter International from a “hold” rating to a “buy” rating and set a $74.00 target price for the company in a research report on Wednesday, January 2nd. Barclays raised Baxter International from an “underweight” rating to an “equal weight” rating and upped their price objective for the company from $67.00 to $72.00 in a research note on Friday, February 1st. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $80.00 price objective on shares of Baxter International in a research note on Friday, February 1st. Four equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $78.13.

COPYRIGHT VIOLATION WARNING: “Nachman Norwood & Parrott Inc Has $266,000 Stake in Baxter International Inc (BAX)” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/nachman-norwood-parrott-inc-has-266000-stake-in-baxter-international-inc-bax/2955854.html.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Further Reading: Why does the United States have a lingering trade deficit?

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.